Showing 1381-1390 of 20878 results for "".
- Exploring Novel Epigenetic Inhibitors in Non-Small Cell Lung Cancerhttps://reachmd.com/news/novel-epigenetic-inhibitors-nsclc/2485389/Chemists at The University of Hong Kong report the development of an ATAC complex inhibitor that targets epigenetic drivers of non-small cel
- No New Safety Signals in Broad Ruxolitinib Dataset, Including AD, Vitiligo, and AAhttps://reachmd.com/news/no-new-safety-signals-in-broad-ruxolitinib-dataset-including-ad-vitiligo-and-aa/2485382/A new safety analysis presented at the 2026 Winter Clinical Dermatology Conference in Maui supporting the long-term tolerability of ruxolitinib cream (Opzelura®, Incyte) in a range of inflammatory skin conditions. The integrat
- Innovations in Crohn's Disease Treatment: Harnessing Genetic Insightshttps://reachmd.com/news/crohns-disease-treatment-genetic-insights/2485376/Researchers at the Broad Institute have reported preclinical small-molecule modulators intended to phen
- Interferon Responses in Rhinovirus: Implications for Pulmonary Practicehttps://reachmd.com/news/interferon-responses-in-rhinovirus-implications-for-pulmonary-practice/2485365/New nasal-epithelium data show that interferon response determines rhinovirus outcomes—shaping symptom burden a
- Understanding Emotional Expressions in Autism: Clinical Implications and Strategieshttps://reachmd.com/news/understanding-emotional-expressions-in-autism-clinical-implications-and-strategies/2485370/Contrary to the longstanding assumption that basic emotions map onto universal facial markers, a comparative study of autistic and non-autistic adults identified divergent kinematic
- Study: Upadacitinib Reduces Inflammation Markers in ADhttps://reachmd.com/news/study-upadacitinib-reduces-inflammation-markers-in-ad/2485380/Upadacitinib (UPA) treatment was associated with significant reductions in biomarkers of systemic inflammation in adults with moderate-to-severe atopic dermatitis (AD), according to a poster presented at Winter Clinical 2026 in Hawaii.
- TYK2 Inhibitor Envudeucitinib Shows Durable Skin Clearance, QoL Gains: Posterhttps://reachmd.com/news/tyk2-inhibitor-envudeucitinib-shows-durable-skin-clearance-qol-gains-poster/2485378/Envudeucitinib, an investigational selective allosteric TYK2 inhibitor, showed sustained achievement of clinically meaningful treat-to-target outcomes in patients with moderate-to-severe plaque psoriasis, according to 52-week data presented at 2026 Winter Clinical
- Advancements in Prostate Cancer Screening: PSA, Risk Models, and Genomic Innovationshttps://reachmd.com/news/advancements-in-prostate-cancer-screening-psa-risk-models-and-genomic-innovations/2485341/Stockholm3, paired with PSA screening, improves detection of clinically significant prostate cancer while reducing overdiagnosis and unnecessary procedures — reframing follow-up decisions after an elevated PSA.
- Microbiome-Informed Precision Nutrition: Bridging the Gap in Metabolic Healthhttps://reachmd.com/news/microbiome-informed-precision-nutrition-bridging-the-gap-in-metabolic-health/2485346/Microbiome-informed precision nutrition is moving from concept to clinical application, offering individualized dietary guidance grounded in host–microbe interactions and metabolic-response profiling. Small randomized controlled trials and other controlled studies s
- Molecular Pathways in Adipose Inflammation: New Insights into Cardiometabolic Riskhttps://reachmd.com/news/molecular-pathways-in-adipose-inflammation-new-insights-into-cardiometabolic-risk/2485348/SAMHD1 phosphorylation links adipose mitochondrial DNA accumulation to NLRP3 inflammasome activation, driving adipose inflammation in obesity and potentially contributing to systemic metabolic dysregulation. Phosphorylation of SAMHD1 reduces its nuclease activity in